The Asia Pacific Veterinary oncology Market would witness market growth of 14.6% CAGR during the forecast period (2020-2026).
Cancers are among the most common diseases that affect dogs. Some of them arise naturally and exhibit certain parallels to human cancers in their physiology and histopathology. There is more, it is seen that there are many more analogies between these two species in the molecular pathways of cancer development. Human oncology is finding more and more effective approaches to diagnose an early illness that results directly in the increased life span of infected animals.
One of the most common trends of cancer treatment is the presence of circulating tumor cells (CTC) of patient blood. These cells are known to be responsible for the development of metastases in distant organs which results in patient death. It is also known that CTC is still present in the early stages of tumor growth in the bloodstream of patients. There is no evidence that the cause for the production of metastasis in dogs is similar, and that the CTC is still found in their bloodstream. Despite rigorous research, there is still no ideal way to separate cancer cells from the blood where they barely exist.
The growing prevalence of zoonotic and foodborne diseases worldwide has driven companies to establish successful testing solutions for both animals and pets. In fact, growth in the demand for veterinary diagnostics is supported by growing spending on animal healthcare and a favorable regulatory scenario for diagnostic approval. The growing use of in vitro diagnostic tests and advanced innovations like nanotechnology, fluorometric diagnosis, biosensors, wearables, and biomarkers has helped this market grow. Research centers and laboratories also report a surge in demand for in-house equipment and techniques for diagnosis.
Based on Animal Type, the market is segmented into Canine and Feline. Based on Therapy, the market is segmented into Chemotherapy, Radiology, Surgery, Immunotherapy and Others. Based on Cancer Type, the market is segmented into Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.
Scope of the Study
Market Segmentation:
By Animal Type

  • Canine and
  • Feline

By Therapy

  • Chemotherapy
  • Radiology
  • Surgery
  • Immunotherapy and
  • Others

By Cancer Type

  • Lymphoma
  • Mast Cell Cancer
  • Mammary & Squamous Cell Cancer and
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled

  • Boehringer Ingelheim International GmbH
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Varian Medical Systems, Inc.
  • PetCure Oncology, LLC (Accelitech, LLC)
  • AB Science SA
  • Rhizen Pharmaceuticals S.A.
  • Nippon Zenyaku Kogyo Co., Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free